Best Project Oncology® podcasts we could find (Updated September 2019)
Related podcasts: Science Tech Health and Well-Being US Business Careers Cancer Medicine Women's Health Interviews Breast Cancer Oncology Research Old Survival Conference PhD Postdocs Scientists Multiple Myeloma Meeting  
Project Oncology® public [search 0]
×
Join millions of Player FM users today to get news and insights whenever you like, even when you're offline. Podcast smarter with the free podcast app that refuses to compromise. Let's play!
Podcast smarter! Player FM is free and easy.
show episodes
 
Project Oncology® presents a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. This series provides cutting-edge updates on cancer biology, diagnosis, and multidisciplinary management, as well as evidence-based recommendations to achieve optimal patient outcomes.
 
Project Oncology® presents a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. This series provides cutting-edge updates on cancer biology, diagnosis, and multidisciplinary management, as well as evidence-based recommendations to achieve optimal patient outcomes.
 
In the American Association for Cancer Research (AACR) scientific podcasts, we provide interviews with cancer researchers about their latest work as well as recordings of AACR teleconferences.
 
The Incubator is a professional development podcast featuring interviews with biology PhDs that have pursued a variety of careers. The interviews focus on their career story and tips for professional development, mental health, and more
 
E
ESMO Open
Rare
 
ESMO Open is the European Society for Medical Oncology’s online-only, peer-reviewed Open Access journal, dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research. The journal is published by BMJ on behalf of ESMO. http://esmoopen.bmj.com/* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is n ...
 
The Information presents Modest Conversations hosted by Sam Lessin, who writes the site's regular 'Modest Conversations' column. Modest Conversations are short conversations with interesting people about technology, culture, politics, and whatever else strikes our fancy.
 
New data were presented at the American Society of Clinical Oncology meeting in June 2010 in Chicago regarding the role of axillary management in the treatment of early stage breast cancer. Join Dr. Harold Burstein as he leads a multidisciplinary case discussion that confronts the question of how these new data may alter your practice now or in the future. Joining Dr. Burstein, an oncologist, are Dr. Jennifer Bellon, MD, an interventional radiologist, and Dr. Mehra Golshan, a surgeon. This c ...
 
Loading …
show series
 
Guest: Charles Geyer, MD With clinical trials showing improvements over the current standard of care for HER2+ early breast cancer, incorporating new data and medications into this treatment paradigm is becoming a top priority. Listen in as Dr. Charles Geyer reviews the emerging approaches to adjuvant therapy in patients with HER2+ early breast ...…
 
Guest: Charles Geyer, MD With clinical trials showing improvements over the current standard of care for HER2+ early breast cancer, incorporating new data and medications into this treatment paradigm is becoming a top priority. Listen in as Dr. Charles Geyer reviews the emerging approaches to adjuvant therapy in patients with HER2+ early breast ...…
 
Despite all the efforts done so far, access to essential drugs in Oncology is still asymmetric. In this podcast, Teresa Amaral, member of the ESMO YOC, interviews Professor Martine Piccart (Scientific Director of the Institut Jules Bordet, Universite Libre de Bruxelles, Belgium) that shares valuable insights on the work that has been done on th ...…
 
Professor Kim Margolin (Department of Medical Oncology, City of Hope National Medical Center, Duarte, California) discusses in this podcast the different treatment strategies as well as the clinical challenge of handling melanoma patients with brain metastases. Brain metastases are a particular problem of melanoma patients, as this complication ...…
 
Host: John J. Russell, MD Guest: Mark Sundermeyer, MD Early diagnosis of non-small cell lung cancer (NSCLC) can increase patients’ rate of survival, and primary care practitioners play an important role in this since they’re oftentimes on the frontlines of care. Here to discuss with Dr. John Russell how primary care practitioners like himself c ...…
 
Host: John J. Russell, MD Guest: Mark Sundermeyer, MD Early diagnosis of non-small cell lung cancer (NSCLC) can increase patients’ rate of survival, and primary care practitioners play an important role in this since they’re oftentimes on the frontlines of care. Here to discuss with Dr. John Russell how primary care practitioners like himself c ...…
 
Welcome to Season 4! This month's guest is Dr. Stefan Avey. He is a Senior Statistician at Janssen Pharmaceuticals. We dive into life at Pharma, prioritization, and how to work from home effectively.
 
Host: Bradley J. Monk, MD, FACS, FACOG There are limited treatment options in the first-line setting for patients with advanced ovarian cancer. Many patients experience disease recurrence or progression with first-line chemotherapy, with approximately 10% to 30% experiencing long-term survival. Anti-angiogenesis agents, such as bevacizumab and ...…
 
Host: Bradley J. Monk, MD, FACS, FACOG There are limited treatment options in the first-line setting for patients with advanced ovarian cancer. Many patients experience disease recurrence or progression with first-line chemotherapy, with approximately 10% to 30% experiencing long-term survival. Anti-angiogenesis agents, such as bevacizumab and ...…
 
Welcome to Season 4! This month's guest is Dr. Gerald Goh. He is an Oncology Segment Manager at Illumina. He discusses life as a marketing expert and how to use your postdoc effectively.By Proteintech.
 
Host: Sophie Balzora, MD, FACG Guest: Carol A. Burke, MD, FACG, FASGE, AGAF, FACP Colonoscopies are an essential procedure, however the effectiveness in detecting colorectal cancer depends heavily on the quality of a patient’s bowel preparation. Here to discuss why some patients choose to skip this preventive procedure and what you can do to he ...…
 
Host: Sophie Balzora, MD, FACG Guest: Jonathan Cohen, MD Joining Dr. Sophie Balzora to discuss the different bowel preparation quality assessment scales available and the advantages of each is Dr. Jonathan Cohen, Clinical Professor of Medicine at NYU School of Medicine. CLEN/1109/2019/USb
 
Host: Sophie Balzora, MD, FACG Guest: Lawrence Hookey, MD Dr. Lawrence Hookey joins Dr. Sophie Balzora to discuss the clinical trial of a next generation low volume prep with proven efficacy and an established safety profile and tolerability data.
 
Host: Sophie Balzora, MD, FACG Guest: Colleen M. Schmitt, MD, MHS, FASGE, FACG An inadequate bowel preparation process experience should never be the factor that keeps patients from undergoing a colonoscopy, yet that’s the case for about one in four colonoscopies. That’s why gastroenterology expert Dr. Colleen Schmitt is here to share her thoug ...…
 
Host: Sophie Balzora, MD, FACG Guest: Carol A. Burke, MD, FACG, FASGE, AGAF, FACP Colonoscopies are an essential procedure, however the effectiveness in detecting colorectal cancer depends heavily on the quality of a patient’s bowel preparation. Here to discuss why some patients choose to skip this preventive procedure and what you can do to he ...…
 
Host: Sophie Balzora, MD, FACG Guest: Jonathan Cohen, MD Joining Dr. Sophie Balzora to discuss the different bowel preparation quality assessment scales available and the advantages of each is Dr. Jonathan Cohen, Clinical Professor of Medicine at NYU School of Medicine. CLEN/1109/2019/USb
 
Host: Sophie Balzora, MD, FACG Guest: Lawrence Hookey, MD Dr. Lawrence Hookey joins Dr. Sophie Balzora to discuss the clinical trial of a next generation low volume prep with proven efficacy and an established safety profile and tolerability data.
 
Host: Sophie Balzora, MD, FACG Guest: Colleen M. Schmitt, MD, MHS, FASGE, FACG An inadequate bowel preparation process experience should never be the factor that keeps patients from undergoing a colonoscopy, yet that’s the case for about one in four colonoscopies. That’s why gastroenterology expert Dr. Colleen Schmitt is here to share her thoug ...…
 
Host: Robert Mocharnuk, MD Guest: Joshua Bauml, MD Lung and bronchus cancer remain the leading cause of cancer-related deaths in the United States among both men and women. The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, the anaplastic lymphoma kinase (ALK) fusion oncogene, ROS1 gen ...…
 
Host: Robert Mocharnuk, MD Guest: Joshua Bauml, MD Lung and bronchus cancer remain the leading cause of cancer-related deaths in the United States among both men and women. The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, the anaplastic lymphoma kinase (ALK) fusion oncogene, ROS1 gen ...…
 
Host: Scott Kopetz, MD, PhD, FACP Guest: Alberto Sobrero, MD Guest: Rui-Hua Xu, MD O cancro colorretal metastático é difícil de gerir e tem múltiplas mutações genéticas, expressões e amplificações, tais como o lado do tumor. E, apesar dos desafios em identificar estas distinções, estas também oferecem pistas essenciais sobre qual a melhor opção ...…
 
Host: Scott Kopetz, MD, PhD, FACP Guest: Alberto Sobrero, MD Guest: Rui-Hua Xu, MD El cáncer colorrectal metastásico es difícil de tratar y presenta varias mutaciones genéticas, expresiones y amplificaciones, tal como la lateralidad del tumor. Y, tal como explican el Dr. Scott Kopetz, el Dr. Rui-Hua Xu y el Dr. Alberto Sobrero, aunque identific ...…
 
Host: Scott Kopetz, MD, PhD, FACP Guest: Alberto Sobrero, MD Guest: Rui-Hua Xu, MD O cancro colorretal metastático é difícil de gerir e tem múltiplas mutações genéticas, expressões e amplificações, tais como o lado do tumor. E, apesar dos desafios em identificar estas distinções, estas também oferecem pistas essenciais sobre qual a melhor opção ...…
 
Host: Scott Kopetz, MD, PhD, FACP Guest: Alberto Sobrero, MD Guest: Rui-Hua Xu, MD El cáncer colorrectal metastásico es difícil de tratar y presenta varias mutaciones genéticas, expresiones y amplificaciones, tal como la lateralidad del tumor. Y, tal como explican el Dr. Scott Kopetz, el Dr. Rui-Hua Xu y el Dr. Alberto Sobrero, aunque identific ...…
 
Host: Chrysalyne D. Schmults, MD, MSCE (Chair) Guest: Omid Hamid, MD Guest: Anokhi Jambusaria, MD, MSCE, FAAD The recent approval of the first immunotherapeutic agent for cutaneous squamous cell carcinoma (cSCC) is changing the way healthcare providers treat patients with inoperable cSCC. In this roundtable discussion, a cSCC survivor draws upo ...…
 
Host: Chrysalyne D. Schmults, MD, MSCE (Chair) Guest: Omid Hamid, MD Guest: Anokhi Jambusaria, MD, MSCE, FAAD The recent approval of the first immunotherapeutic agent for cutaneous squamous cell carcinoma (cSCC) is changing the way healthcare providers treat patients with inoperable cSCC. In this roundtable discussion, a cSCC survivor draws upo ...…
 
Host: Scott Kopetz, MD, PhD, FACP Guest: Alberto Sobrero, MD Guest: Rui-Hua Xu, MD Metastatic colorectal cancer is difficult to manage and has multiple genetic mutations, expressions, and amplifications, such as tumor sidedness. And while identifying these distinctions can be challenging, they offer essential clues to which treatment option is ...…
 
Host: Scott Kopetz, MD, PhD, FACP Guest: Alberto Sobrero, MD Guest: Rui-Hua Xu, MD Metastatic colorectal cancer is difficult to manage and has multiple genetic mutations, expressions, and amplifications, such as tumor sidedness. And while identifying these distinctions can be challenging, they offer essential clues to which treatment option is ...…
 
Sam and Erik discuss ISAs / and the future of equity investing in people / personal income vs. debt financing.By Sam Lessin.
 
Host: Jennifer Caudle, DO Guest: Suhail K. Kanchwala, MD Improving his patients’ post-surgical experience was Dr. Suhail Kanchwala's goal when he sought to develop a new method for autologous breast reconstruction. The result of his search has brought a new technique to the field, along with an array of benefits for patients, including reductio ...…
 
Host: Jennifer Caudle, DO Guest: Suhail K. Kanchwala, MD Improving his patients’ post-surgical experience was Dr. Suhail Kanchwala's goal when he sought to develop a new method for autologous breast reconstruction. The result of his search has brought a new technique to the field, along with an array of benefits for patients, including reductio ...…
 
Host: Shira Johnson, MD Guest: Edmond Bendaly, MD, FACP From VEGF and EGFR-targeted therapies to emerging immunotherapies, there are several treatment options available to mCRC patients…but that also means that there’s several factors you need to think about before deciding which option is best for each individual patient. Here to break everyth ...…
 
Guest: Richard Kim, MD Join Dr. Richard Kim of Moffitt Cancer Center as he reveals how the sidedness of a mCRC tumor affects not only the prognosis, but also the biologic you use for each individual patient. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ...…
 
Guest: Richard Kim, MD Performing KRAS testing is an essential step clinicians need to take to determine which therapeutic option is best. In fact, skipping this step can actually be detrimental to patients. Here to talk about the important role of KRAS testing in metastatic colorectal cancer is Dr. Richard Kim, Medical Oncologist at Moffitt Ca ...…
 
Guest: Richard Kim, MD There’s much to consider when it comes to determining which therapeutic option is best for your metastatic colorectal cancer patients, which is why Dr. Richard Kim is here to walk us through his thought process using this patient case review. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-c ...…
 
Guest: Edmond Bendaly, MD, FACP Dr. Edmond Bendaly from the Cancer Committee at Marion General Hospital in Indiana shares a patient case that stands out from the rest—and proves the importance of consistently monitoring for side effects. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series ...…
 
Host: Shira Johnson, MD Guest: Edmond Bendaly, MD, FACP From VEGF and EGFR-targeted therapies to emerging immunotherapies, there are several treatment options available to mCRC patients…but that also means that there’s several factors you need to think about before deciding which option is best for each individual patient. Here to break everyth ...…
 
Guest: Richard Kim, MD Join Dr. Richard Kim of Moffitt Cancer Center as he reveals how the sidedness of a mCRC tumor affects not only the prognosis, but also the biologic you use for each individual patient. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ...…
 
Guest: Richard Kim, MD Performing KRAS testing is an essential step clinicians need to take to determine which therapeutic option is best. In fact, skipping this step can actually be detrimental to patients. Here to talk about the important role of KRAS testing in metastatic colorectal cancer is Dr. Richard Kim, Medical Oncologist at Moffitt Ca ...…
 
Guest: Richard Kim, MD There’s much to consider when it comes to determining which therapeutic option is best for your metastatic colorectal cancer patients, which is why Dr. Richard Kim is here to walk us through his thought process using this patient case review. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-c ...…
 
Guest: Edmond Bendaly, MD, FACP Dr. Edmond Bendaly from the Cancer Committee at Marion General Hospital in Indiana shares a patient case that stands out from the rest—and proves the importance of consistently monitoring for side effects. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series ...…
 
Host: Alice T. Shaw, MD, PhD The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCL ...…
 
Host: Alice T. Shaw, MD, PhD The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCL ...…
 
The IMpassion130 trial was a global, randomized, double-blind, Phase III study of Atezolizumab + nab-paclitaxel vs. placebo + nab-paclitaxel in treatment naïve locally advanced or metastatic triple negative breast cancer patients. Here, progression free survival was statistically significantly longer in patients treated with the combination of ...…
 
Radiotherapy to the primary tumor has been a controversially discussed intervention in patients with newly diagnosed metastatic prostate cancer. Results of the STAMPEDE trial indicate that overall no survival advantage can be achieved by the addition of radiotherapy however subgroups might actually have a benefit. Here, patients with low volume ...…
 
This month’s guest is Dr. Briana Konnick. She is the assistant director of career development at University of Chicago. She discusses how to transform your career aspirations from "not academia" to a bona fide job. Highlights include resources for career exploration(6:45) and a deep-dive into linkedin as a tool for landing that coveted job (22:34).…
 
Host: James L. Gulley, MD, PhD, FACP Guest: Scott Kopetz, MD, PhD, FACP Guest: Luis Paz-Ares, MD, PhD The presence of transforming growth factor-beta (TGF-β) in the tumor microenvironment plays a main role in limiting the clinical efficacy of anti-PD-1/PD-L1 checkpoint inhibitors. Not only does TGF-β suppress the normal anti-tumor action of nat ...…
 
Host: James L. Gulley, MD, PhD, FACP Guest: Scott Kopetz, MD, PhD, FACP Guest: Luis Paz-Ares, MD, PhD The presence of transforming growth factor-beta (TGF-β) in the tumor microenvironment plays a main role in limiting the clinical efficacy of anti-PD-1/PD-L1 checkpoint inhibitors. Not only does TGF-β suppress the normal anti-tumor action of nat ...…
 
In this podcast, Marina Parry, ESMO Open Digital Editor, speaks to Elana Anastasio, Partnership Outreach Manager, and Brett Tomson, Scientific Outreach Manager, both from the Metastatic Breast Cancer (MBC) Project team at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, USA.The MBCproject is a novel model of a patient-partner ...…
 
This month’s guest is Dr. Liz Noblin. She is the research project manager at 23andMe, a leading genomics company. She discusses the merits of doing a postdoc before going into industry, how to learn Big Data analysis on your own, finding your “superpower”, and more!
 
Google login Twitter login Classic login